Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Clinical implications of GRHL3 protein expression in breast cancer.

Xu H, Liu C, Zhao Z, Gao N, Chen G, Wang Y, Cui J.

Tumour Biol. 2014 Mar;35(3):1827-31. doi: 10.1007/s13277-013-1244-7. Epub 2013 Dec 22.

PMID:
24363083
2.

Nestin: predicting specific survival factors for breast cancer.

Gao N, Xu H, Liu C, Xu H, Chen G, Wang X, Li Y, Wang Y.

Tumour Biol. 2014 Mar;35(3):1751-5. doi: 10.1007/s13277-013-1548-7. Epub 2014 Jan 18.

PMID:
24443256
3.

Clinicopathological significance and prognostic value of Xeroderma pigmentosum complementary group C (XPC) expression in sporadic breast cancer patients.

Bai X, Jin F, Fu Y, Yu Z, Zhao L, Ren J, Li Y, Jiao X, Zhao H, Yao W, Mi X, Wang E, Olopade OI, Zhou M, Wei M.

Med Oncol. 2012 Sep;29(3):1543-53. doi: 10.1007/s12032-011-0086-7. Epub 2011 Oct 30.

PMID:
22038723
4.

Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers.

De Brot M, Rocha RM, Soares FA, Gobbi H.

Pathology. 2012 Jun;44(4):303-12. doi: 10.1097/PAT.0b013e3283534bcb.

PMID:
22544210
5.

Quantitative immunohistochemical analysis and prognostic significance of TRPS-1, a new GATA transcription factor family member, in breast cancer.

Chen JQ, Litton J, Xiao L, Zhang HZ, Warneke CL, Wu Y, Shen X, Wu S, Sahin A, Katz R, Bondy M, Hortobagyi G, Berinstein NL, Murray JL, Radvanyi L.

Horm Cancer. 2010 Feb;1(1):21-33. doi: 10.1007/s12672-010-0008-8. Epub 2010 Feb 13.

PMID:
21761348
6.

Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis.

Kobayashi T, Tsuda H, Moriya T, Yamasaki T, Kikuchi R, Ueda S, Omata J, Yamamoto J, Matsubara O.

Breast Cancer Res Treat. 2010 Oct;123(3):733-45. doi: 10.1007/s10549-009-0672-y. Epub 2009 Dec 18.

PMID:
20020198
7.

High levels of γ-glutamyl hydrolase (GGH) are associated with poor prognosis and unfavorable clinical outcomes in invasive breast cancer.

Shubbar E, Helou K, Kovács A, Nemes S, Hajizadeh S, Enerbäck C, Einbeigi Z.

BMC Cancer. 2013 Feb 1;13:47. doi: 10.1186/1471-2407-13-47.

8.

High expression of LC3B is associated with progression and poor outcome in triple-negative breast cancer.

Zhao H, Yang M, Zhao J, Wang J, Zhang Y, Zhang Q.

Med Oncol. 2013 Mar;30(1):475. doi: 10.1007/s12032-013-0475-1. Epub 2013 Feb 1.

PMID:
23371253
9.

Elevated cyclin B2 expression in invasive breast carcinoma is associated with unfavorable clinical outcome.

Shubbar E, Kovács A, Hajizadeh S, Parris TZ, Nemes S, Gunnarsdóttir K, Einbeigi Z, Karlsson P, Helou K.

BMC Cancer. 2013 Jan 2;13:1. doi: 10.1186/1471-2407-13-1.

10.

Histone demethylase GASC1--a potential prognostic and predictive marker in invasive breast cancer.

Berdel B, Nieminen K, Soini Y, Tengström M, Malinen M, Kosma VM, Palvimo JJ, Mannermaa A.

BMC Cancer. 2012 Nov 14;12:516. doi: 10.1186/1471-2407-12-516.

11.

Girdin protein: a new potential distant metastasis predictor of breast cancer.

Liu C, Zhang Y, Xu H, Zhang R, Li H, Lu P, Jin F.

Med Oncol. 2012 Sep;29(3):1554-60. doi: 10.1007/s12032-011-0087-6. Epub 2011 Nov 25.

PMID:
22116776
12.

Clinicopathological significance of ERCC1 expression in breast cancer.

Gerhard R, Carvalho A, Carneiro V, Bento RS, Uemura G, Gomes M, Albergaria A, Schmitt F.

Pathol Res Pract. 2013 Jun;209(6):331-6. doi: 10.1016/j.prp.2013.02.009. Epub 2013 Mar 6.

PMID:
23702380
13.

Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma.

Zhao P, Lu Y, Jiang X, Li X.

Cancer Sci. 2011 May;102(5):1107-11. doi: 10.1111/j.1349-7006.2011.01894.x. Epub 2011 Feb 28.

14.

Expression of ALDH1 and TGFβ2 in benign and malignant breast tumors and their prognostic implications.

Zheng R, Wang J, Wu Q, Wang Z, Ou Y, Ma L, Wang M, Wang J, Yang Y.

Int J Clin Exp Pathol. 2014 Jun 15;7(7):4173-83. eCollection 2014.

15.

High fibroblast growth factor 19 (FGF19) expression predicts worse prognosis in invasive ductal carcinoma of breast.

Buhmeida A, Dallol A, Merdad A, Al-Maghrabi J, Gari MA, Abu-Elmagd MM, Chaudhary AG, Abuzenadah AM, Nedjadi T, Ermiah E, Al-Thubaity F, Al-Qahtani MH.

Tumour Biol. 2014 Mar;35(3):2817-24. doi: 10.1007/s13277-013-1374-y. Epub 2013 Nov 19.

PMID:
24248542
16.

Aldehyde dehydrogenase 1 expression predicts poor prognosis in triple-negative breast cancer.

Ohi Y, Umekita Y, Yoshioka T, Souda M, Rai Y, Sagara Y, Sagara Y, Sagara Y, Tanimoto A.

Histopathology. 2011 Oct;59(4):776-80. doi: 10.1111/j.1365-2559.2011.03884.x.

PMID:
22014057
17.

CX3CL1 expression is associated with poor outcome in breast cancer patients.

Tsang JY, Ni YB, Chan SK, Shao MM, Kwok YK, Chan KW, Tan PH, Tse GM.

Breast Cancer Res Treat. 2013 Aug;140(3):495-504. doi: 10.1007/s10549-013-2653-4. Epub 2013 Aug 4.

PMID:
23912959
18.

Grb14 as an independent good prognosis factor for breast cancer patients treated with neoadjuvant chemotherapy.

Huang O, Jiang M, Zhang X, Xie Z, Chen X, Wu J, Liu H, Shen K.

Jpn J Clin Oncol. 2013 Nov;43(11):1064-72. doi: 10.1093/jjco/hyt130. Epub 2013 Sep 12.

19.

Expression of Abl interactor 1 and its prognostic significance in breast cancer: a tissue-array-based investigation.

Wang C, Tran-Thanh D, Moreno JC, Cawthorn TR, Jacks LM, Wang DY, McCready DR, Done SJ.

Breast Cancer Res Treat. 2011 Sep;129(2):373-86. doi: 10.1007/s10549-010-1241-0. Epub 2010 Nov 3.

PMID:
21046228
20.

Reduced nuclear expression of transcription factor AP-2 associates with aggressive breast cancer.

Pellikainen J, Kataja V, Ropponen K, Kellokoski J, Pietiläinen T, Böhm J, Eskelinen M, Kosma VM.

Clin Cancer Res. 2002 Nov;8(11):3487-95.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk